Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palisade Bio (PALI) Gains from Sales and Divestitures (2016 - 2023)

Palisade Bio has reported Gains from Sales and Divestitures over the past 6 years, most recently at $34653.0 for Q3 2023.

  • Quarterly Gains from Sales and Divestitures changed N/A to $34653.0 in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $34653.0 through Sep 2023, changed N/A year-over-year, with the annual reading at $3814.0 for FY2020, 56.83% down from the prior year.
  • Gains from Sales and Divestitures was $34653.0 for Q3 2023 at Palisade Bio, up from $12662.0 in the prior quarter.
  • Over five years, Gains from Sales and Divestitures peaked at $34653.0 in Q3 2023 and troughed at $3814.0 in Q4 2020.
  • The 3-year median for Gains from Sales and Divestitures is $8835.0 (2019), against an average of $13492.8.
  • Year-over-year, Gains from Sales and Divestitures plummeted 87.81% in 2019 and then tumbled 56.83% in 2020.
  • A 3-year view of Gains from Sales and Divestitures shows it stood at $8835.0 in 2019, then tumbled by 56.83% to $3814.0 in 2020, then surged by 808.57% to $34653.0 in 2023.
  • Per Business Quant, the three most recent readings for PALI's Gains from Sales and Divestitures are $34653.0 (Q3 2023), $12662.0 (Q2 2023), and $3814.0 (Q4 2020).